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Abstract. Front line therapy for the treatment of patients aected by chronic 
myeloid leukemia (CML) is based on the administration of tyrosine kinase 
inhibitors, namely imatinib or, more recently, axitinib. Although imatinib is 
highly eective and represents an example of a successful molecular targeted 
therapy, the appearance of resistance is observed in a proportion of patients, 
especially those in advanced stages. In this work, we investigate the appearance 
of resistance in patients aected by CML, by modeling the evolutionary dynamics 
of cancerous cell populations in a simulated patient treated by an intermittent 
targeted therapy. We simulate, with the Monte Carlo method, the stochastic 
evolution of initially healthy cells to leukemic clones, due to genetic mutations 
and changes in their reproductive behavior. We ﬁrst present the model and its 
validation with experimental data by considering a continuous therapy. Then, 
we investigate how ﬂuctuations in the number of leukemic cells aect patient 
response to the therapy when the drug is administered with an intermittent 
time scheduling. Here we show that an intermittent therapy (IT) represents a 
valid choice in patients with high risk of toxicity, despite an associated delay 
to the complete restoration of healthy cells. Moreover, a suitably tuned IT can 
reduce the probability of developing resistance.
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1. Introduction
Although cancer is a leading cause of death in the world, little is still known about the 
mechanism of its growth and destruction [1, 2]. In fact, cancer growth dynamics is a 
typical example of complex dynamics in which the role of ﬂuctuations can be relevant, 
as in biological systems [3–18].
Chronic myeloid leukemia (CML) is a blood cancer causing an overproduction of 
myeloid cells (one of the main types of white blood cells) which are released into the 
blood when they are immature and unable to work properly. This generally leads to 
an increased risk of infection and strongly limits the production of healthy red cells 
and platelets. The chromosome abnormality that causes the development of CML is 
the Philadelphia (Ph) chromosome and consists of a reciprocal translocation occur-
ring in both stem cells and progenitors, giving rise to the BCR–ABL gene. BCR is the 
breakpoint cluster region, and ABL stands for Abelson, the name of a leukemia virus 
carrying a similar protein [19].
Nowadays, the front line therapy for the treatment of CML is based on the admin-
istration of highly eective tyrosine kinase inhibitors (TKIs) which are able to turn o 
the signal produced by the Ph chromosome and inhibit the proliferation of leukemic 
hematopoietic cells. The administration of TKIs represents the ﬁrst example of a suc-
cessful molecular targeted therapy. These inhibitors greatly reduce the growth of the 
tumor clone but can cause toxicity in fully treated patients [20]. Moreover, a great 
number of genetic alterations due to a chromosomal instability aects immature leuke-
mic cells. Speciﬁcally, the basis for the development of acquired resistance to imatinib-
like drugs in a relevant fraction of patients is point mutations [21, 22]. In patients 
harboring such mutations, novel second line TKIs have demonstrated encouraging 
ecacy, obtaining hematologic and cytogenetic remission in the majority of patients 
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with acquired resistance in chronic phase disease. Unfortunately, in advanced stages of 
the disease, responses are more limited and relapse is common.
Recently, in clinical studies devoted to the reduction of hematologic toxicity in 
patients aected by CML, a new therapeutic approach, based on the intermittent 
dosage of TKIs, has been investigated [20, 23, 24]. In fact, it was shown that an inter-
mittent therapy (IT) can be considered a good alternative to standard daily dosing 
in patients with persistent signs of myelotoxicity, without compromising the patient 
cytogenetic response. Moreover, in recent clinical studies on the treatment of advanced 
prostate cancer and breast cancer, the introduction of breaks in long-term anticancer 
treatments can prolong tumor response to the therapy [25–27]. In other words, IT 
can give rise to inhibition and disruption of the most resistant or dependent cancer 
clones. In particular in CML, a temporary interruption of imatinib-like therapy has 
signiﬁcantly reduced the presence of leukemic cells showing the malignant mutations 
in a resistant patient [28, 29].
Along these lines, and driven by patient necessity to eectively reduce drug toxicity 
during a continuous TKIs-based treatment of CML, and the need to design a strat-
egy to stave o resistance, we have developed a model of leukemic cell evolutionary 
dynamics to investigate the response of simulated patients treated by an imatinib-like 
IT. In particular in this work, we study the ﬂuctuations in cancer growth dynamics in 
patients aected by CML and developing resistance to the standard therapy by the 
Monte Carlo (MC) method. The evolutionary dynamics of cancerous cell populations is 
modeled in numerically simulated patients treated by a continuous or an intermittent 
targeted therapy. In our model, initially healthy cells can experience genetic muta-
tions and change their reproductive behavior, becoming leukemic clones. We simulate 
a TKIs-based treatment of CML by modifying the ﬁtness and death rate of cancerous 
cells.
Here we show that IT could represent a valid alternative in patients with high risk 
of toxicity, being a suitably tuned pulsed therapy more eective in reducing the prob-
ability of developing resistance. We start out, in section 2, with a description of the 
model, giving the details of the simulation process. Results are reported in section 3 and 
conclusions are drawn in section 4.
2. Model of CML evolution
In this section we describe the model used to reproduce the dynamics of leukemic cells 
in patients aected by CML. The time evolution of CML has been analyzed using 
deterministic approaches [30–33] as much as models based on stochastic approaches 
[2, 5, 8, 10, 14, 34–38]. According to clinical studies on cancer genetics [39, 40], which 
analyze the time behaviour of the level of BCR–ABL positive cells in patients treated 
with imatinib, both deterministic and stochastic models consider that leukemia initia-
tion coincides with the occurrence of multiple mutations in a single non-dierentiated 
blood cell. In our model, the blood is composed of four cell populations: healthy cells 
(type-0), ﬁrst-mutated cells (type-1), double-mutated leukemic cells (type-2) and resis-
tant leukemic clones (type-3). Moreover, each population consists of the sum of stem 
cells, progenitors, dierentiated and terminally dierentiated cells.
Intermittent therapies and fluctuations in chronic myeloid leukemia
4doi:10.1088/1742-5468/2016/05/054032
J. S
tat. M
ech. (2016) 054032
Stem cells, which possess an indeﬁnite potential for self-renewal [32], or progenitors 
[19] can experience mutations which cause the appearance of leukemic dierentiated and 
terminally dierentiated cells. Therefore, we model mutation rates and ﬁtness by con-
sidering the averages over the sub-populations of stem cells and progenitors. Conversely, 
death rates are obtained as averages over the values of all four sub-populations.
To simulate the cancer dynamics we study the time evolution of N  =  104 cells, a 
value much smaller than the typical number of blood cells contained in a human organ-
ism, but large enough to permit a statistical analysis of the cancer evolution in a given 
blood ‘region’. The cancer dynamics is obtained by keeping constant the total number 
of blood cells, which is a reasonable assumption for the cells in a single blood compart-
ment. An event of reproduction, mutation or death occurs as a random outcome of a 
Monte Carlo simulation, according to the procedure already applied in numerous theor-
etical investigations [8, 33–36]. In particular, cell reproduction, mutation and death 
are assumed to occur asyncronously. In other words, the cell dynamics is simulated 
by a stochastic process consisting, at each time step, of a birth and a death event i.e. 
a Moran process [41]. The logical steps for a single reproduction and death event are 
schematically shown in ﬁgure 1. The birth process is simulated by randomly choosing 
one of the N cells with a probability which is proportional to its reproductive rate. This 
is set equal to 1 for cells of type-0 and type-1. The ﬁtness of leukemic cells is assumed 
to be 10 times that of normal cells, when no therapy is present. In the presence of 
imatinib-based treatment this value becomes lower for the cells sensitive to the drug, 
while resistant leukemic cells maintain unaltered ﬁtness.
In this work, in the presence of imatinib, the reproductive capability of the dou-
ble-mutated leukemic cells (type-2) is assumed to decrease to a speciﬁc value, which 
depends on the number of type-2 leukemic cells present at that time, according to the 
following relation
( ) ( ) ( ) ( ( ( ) ( ( ) )) )= − ⋅ − + +F t C C N t N t N C/ 0.5 0.5 /C C C2 1 2 2 2 23 3 3 (1)
with C1  =  0.985, C2  =  0.01, C3  =  0.5 and N the total number of cells. The values of such 
parameters have been chosen in order to match the response of type-2 leukemic cells to 
that experimentally observed in patients treated by an imatinib-based targeted therapy 
[2, 32]. In ﬁgure 2(a) we show the behavior of the ﬁtness of type-2 leukemic cells as a 
function of the number of leukemic cells sensitive to the therapy given by equation (1). 
The parameters have been selected in order to leave the modeled percentage as an 
upper level of the clinical data (conservative approach).
Figure 1. Flowchart of our system of cells. fi (with i  =  0, 1, 2, 3) are the normalized 
ﬁtness rates and di the corresponding death rates; M01, M12, M23 are mutation rates 
for transitions from type-0 to type-1 cells, from type-1 to type-2 cells and from 
type-2 to type-3 cells, respectively.
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Mutations from healthy (type-0) to ﬁrst-mutated (type-1) cells and from type-1 to 
double-mutated (type-2) cells, i.e. leukemic cells sensitive to the therapy, occur with 
rates M01  =  0.0005 and M12  =  0.002, respectively. These values are in a good agree-
ment with those used in previous theoretical works [8, 32]. Simulations performed 
with dierent values of M01 and M12 showed dierences only in the waiting time 
before the ﬁrst leukemic cell appears, but no signiﬁcant modiﬁcations occur in the 
successive development of leukemia. In our model, taking into account the apoptosis 
that tyrosine kinase induces in BCR–ABL expressing cells [42, 43], the death rate 
of the type-2 leukemic cells can be enhanced by acting on the drug being adminis-
tered, while the net reproductive capability of the resistant leukemic cells (type-3) is 
not inﬂuenced by the imatinib-based treatment. Finally, back mutations and direct 
trans itions from healthy (type-0) to leukemic cells (type-2) or to resistant clones 
(type-3) are neglected.
To give a more realistic description of the eects produced by drug administration 
on the simulated cancer evolution, in our model the response of the cells to the therapy 
can occur through multiple genetic changes, which cause an enhancement of the muta-
tion rates. This idea agrees with experimental ﬁndings in which, due to certain muta-
tion events, increased rates are observed in successive mutations [44, 45]. Speciﬁcally, 
in an increasing number of patients clinical studies evidenced the onset of resistance to 
imatinib within a period of two years after the beginning of the treatment.
The appearance of resistance determines a worsening of the disease with a passage 
to the chronic, accelerated and blast crisis phases [29]. In these conditions the number 
of immature leukemic cells (myeloblasts) in the blood or bone marrow increases [46]. 
We take into account this behaviour by assuming that the type-2 cells undergo a muta-
tion, becoming type-3 cells at a rate M23 whose value is not constant. In particular, M23 
increases as a function of the number N2 of leukemic double-mutated cells. The depend-
ence of M23 on N2 has been analyzed by using clinical data showing the frequency of 
acquired hematologic resistance with respect to the number of myeloblasts in the blood. 
Figure 2. (a) Fitness of type-2 leukemic cells as a function of the number of 
leukemic cells sensitive to the therapy, calculated by equation (1) and reproducing 
the experimental behavior, of the frequency of deleterious mutations associated 
with the appearance of resistance as a function of disease progression [29]. 
(b) Mutation rate M23 calculated by equation (2) as a function of type-2 leukemic 
cells.
(a) (b)
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On this basis, adopting the standard deﬁnition of CML phases cited above [29], the 
following equation has been obtained
( ( ) )= + ⋅ − −M a b d1 e / .N c23 /2 (2)
Here = ⋅ −a 2 10 4, = ⋅b 8.5 103, = ⋅c 2.5 103 and = ⋅d 4 107 are the values that allow us 
to obtain from equation (2) theoretical values in the best agreement with exper imental 
ﬁndings [29]. The latency value of the mutation rate from type-2 to type-3 cells is 
= ⋅ −M 2 1023 4. This increases, doubling in value for increasing values of the number 
N2 of immature cells. In ﬁgure 2(b) we show the behavior of the mutation rate M23 
as a function of the number of leukemic cells sensitive to the therapy according to 
equation (2).
In ﬁgure 3 we show the dead-event normalized space as a function of the number N 
of the type-2 leukemic cells. In particular, this picture represents the probability space 
for all four cell populations to experience a death event, when a random number in the 
MC procedure is extracted between 0 and 1. These probabilities are identical (25%) 
at low numbers of type-2 leukemic cells. When this number increases, the probability 
associated with a death event for a type-2 leukemic cell also increases, while remaining 
equally distributed among the other three cell populations.
For continuous drug therapy the simulation results of the percent age of leukemic 
cells as a function of time, compared with the BCR–ABL percentage values, observed 
in clinical investigations and reported in [32] (red squares) and [2] (blue squares) are 
shown in ﬁgure 4. The functional behavior of the number of leukemic cells with time is 
decreasing during the ecacy phase of the therapy and subsequently increases because 
of the appearance of resistance. Our theoretical results (continuous green line) are in 
good agreement with the experimental ones, thus validating our model.
The appearance of drug resistance within two years after the beginning of the ther-
apy suggests that the mutation from drug-sensitive (type-2) to drug-resistant (type-3) 
leukemic cells can occur as an evolutionary adaptation of the cancerous cells to the 
drug. It is therefore reasonable to hypothesize that, when the therapy is interrupted, 
Figure 3. Normalized probability space for all four cell populations to experience 
a death event, when a random number in the Monte Carlo procedure is extracted 
between 0 and 1, as a function of the number of type-2 leukemic cells.
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the mutation rate M23 decreases, with a strong reduction of the risk that the patient 
develops resistance to the drug.
In our numerical analysis the time is measured in units of cell divisions. Assuming 
that 500 cell divisions occur in one day, the time necessary to completely restore 
healthy cells is almost 200 d. This result agrees with experimental data observed in 
clinical studies with an optimal response to the therapy [2, 32].
3. Results and discussion
In this section we analyze the ﬂuctuations in the patient response to TKIs-based thera-
pies, characterized by dierent drug administration schedules. With the proportion of 
malignant cells close to 99% at the time of diagnosis, the initial condition in our simu-
lations is that all the patient cells are leukemic type-2. Nevertheless, healthy cells and 
ﬁrst-mutated cells participate in the reproduction process, because we are simulating the 
evolutionary dynamics of all four subpopulations of cells and stem cells are always able 
to produce them. In this context, the resistant clone may originate only by a stochastic 
process of mutation from the leukemic phenotype. Therefore, type-3 cells acquire the 
chance to reproduce themselves only after the ﬁrst resistant cell is generated.
With the standard daily dosage of TKIs suciently high to persist in patient plasma 
for about 24 h [20, 47], standard CML treatment is achieved with continuous therapy. 
In order to lower the number of leukemic cells as rapidly as possible (ﬁgure 3), dur-
ing the ﬁrst 200 d of treatment our patients are simulated as receiving imatinib with 
the standard daily dosage, corresponding to a fully continuous modeled therapy. This 
choice has been made ﬁrstly because, for patient health, it is necessary to restore a suit-
able level of red cells and platelets and, secondly, to reduce the probability of develop-
ing resistance, which is greater when the number of immature leukemic cells is higher.
The occurrence of a genetic alteration that leads a leukemic cell to become resistant 
to the therapy is a stochastic process. Hence, in order to give a statistical signiﬁcance to 
our descriptions, we have repeated every simulation ⋅5 103 times. This means that a total 
Figure 4. Comparison between the BCR–ABL1/BCR percentage calculated by 
our model as a function of time (green line) and the clinical ﬁndings reported by 
[32] (red squares) and [2] (blue squares).
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number of 5000 patients are simulated in this study. Our simulated patients, subjected 
to a continuous therapy for the ﬁrst 200 d, are then treated by three dierent thera-
peutic strategies characterized by: (i) continuous drug administration (namely, ‘CT’), 
(ii) long interruptions (7 d of stop after 21 of continuous therapy, namely ‘IT21-7’) 
or (iii) short breaks (one day yes, one day no, namely ‘IT1’).
First of all we have estimated the mean waiting time for the development of resist ance 
and the average increasing trend in the number of resistant cells. The mean waiting time 
before the first appearance of a resistant type-3 cell is calculated by averaging over all 
patients developing resistance. The results of our calculations are shown in ﬁgure 5. We 
see that a time delay is associated with dierent therapies. In particular the longest wait-
ing time is achieved when an IT1 therapy is administrated (green dotted line in the ﬁgure).
In ﬁgure 6 we show the temporal evolution of the average numbers of the dierent 
cell populations. Speciﬁcally healthy and ﬁrst-mutated cells (green lines), leukemic 
cells still sensitive to the therapy (red lines) and resistant leukemic clones (blue lines). 
Continuous lines refer to the continuous therapy. Dashed and dotted lines represent an 
IT21–7 and IT1 therapy with time breaks of 7 and 1 d, respectively.
In ﬁgure 7 we show how intrinsic ﬂuctuations within the cancerous system drive the 
number of patients developing resistance as a function of the time Tstart at which the ﬁrst 
resistant clone is generated, for the three therapeutic approaches here explored: continu-
ous therapy (blue), IT1 (green), and IT21-7 (red). Data corresponding to the ﬁrst 200 
d of continuous treatment, being common among the three modeled therapies, are not 
considered in this study. After the ﬁrst 200 d of continuous treatment, we recorded the 
number of patients having developed resistance, and detected the presence of the ﬁrst 
type-3 leukemic cell, at a speciﬁc time Tstart, by adopting a sampling rate of 7 d for a total 
duration of two years from the beginning of the treatment. Greater ﬂuctuations in the 
number of patients developing resistance are observed in the presence of an IT21-7 drug 
administration strategy. This is partly due to the assumption of considering in the model 
the appearance of resistance as an evolutionary process of reaction against the presence of 
the drug in the patient’s body. As a matter of fact, this assumption is responsible for the 
periodical missing detection of patients developing resistance in IT21-7 therapy (missing 
Figure 5. Average trend of resistance development under CT (solid line) and IT 
with breaks of 7 (dashed red line) and 1 (dotted green line) days. The mean waiting 
time before the ﬁrst appearance of a resistant type-3 cell is calculated by averaging 
over all patients developing resistance.
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red lines in ﬁgure 7), but this interruption inevitably causes a drastic increase in the num-
ber of type-2 leukemic cells. In ﬁgure 7 we also report the number of simulated patients 
who did not develop resistance after two years of treatment. In this respect, we have 
found that lower numbers of patients developing resistant leukemic clones are achieved 
when an IT1 therapy is administered (green data in ﬁgure 7).
The crucial point for patient long-term survival to CML is avoiding those mutations 
causing a type-2 leukemic cell to become type-3 resistant to the therapy. In our model 
the occurrence probability for such harmful mutations depends on the presence of the 
drug, and increases with the number of type-2 leukemic cells. This is the reason why 
the study of ﬂuctuations in the number of type-2 leukemic cells is so crucial for a clear 
estimate of the balance between the beneﬁts of the therapy and the risk of developing 
cancer resistance.
Figure 6. Temporal evolution of cell populations: healthy and ﬁrst-mutated cells 
(green lines), leukemic cells still sensitive to the therapy (red lines) and resistant 
leukemic clones (blue lines). These values of the number of cells represent averages 
over 5000 simulated patients. Continuous lines refer to CT. Dashed and dotted lines 
represent an IT21-7 and IT1 therapy with time breaks of 7 and 1 d, respectively.
Figure 7. Number of patients developing resistance as a function of the time Tstart 
at which the ﬁrst resistant clone is generated. The three therapeutic approaches 
are explored: CT (blue), IT1 (green) and IT21-7 (red). Inside the ﬁgure we also 
report the number of simulated patients who did not develop resistance after two 
years of treatment.
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Figure 8. Number of type-2 leukemic cells for the 5000 simulated patients (left 
panels) and distributions of simulated patients among the type-2 leukemic cells 
(right panels). Blue symbols/curves refer to patients treated by CT. Red and green 
diamonds/curves are used for ITs with breaks of 7 d and 1 d, respectively. The time 
window starts at the 214th day, after 200 d of continuous drug administration, by 
adopting a sampling rate of two weeks.
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In ﬁgure 8 (left panels) we show how the number of type-2 leukemic cells is distrib-
uted among all the simulated patients after the ﬁrst 200 d, at ﬁxed time steps of 14 d 
for 8 weeks. Continuations of ﬁgure 8 with the subsequent 8 and 16 weeks are shown 
Figure 9. Continuation of ﬁgure 8. Blue symbols/curves refer to patients treated 
by CT. Red and green diamonds/curves are used for ITs with breaks of 7 d and 1 
d, respectively.
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in ﬁgures 9 and 10, respectively. In all three ﬁgures, the blue colour is used for patients 
treated by CT, red for IT21-7 and green for IT1. Figures 8–10 (right panels) also show 
the distribution of patients with a given number of type-2 leukemic cells. Of course 
Figure 10. Continuation of ﬁgure 9. Blue symbols/curves refer to patients treated 
by CT. Red and green diamonds/curves are used for ITs with breaks of 7 d and 1 
d, respectively.
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the best results, in terms of lower levels of type-2 leukemic cells, are achieved with a 
continuous therapy. However, the results shown in ﬁgures 8–10 demonstrate that IT 
could also represent a valid choice in patients who cannot be given the drug continu-
ously due, for example, to a problem of toxicity. In particular, we ﬁnd that the number 
of type-2 leukemic cells in patients treated by IT21-7 shows a trend similar to that 
of CT for the ﬁrst three weeks, while a characteristic peak (red in ﬁgure 8) is instead 
detected during the subsequent seven days without treatment. The number of type-2 
leukemic cells is lowered during the subsequent 21 d of drug administration, keeping a 
ﬂuctuating but still acceptable overall level of leukemic cells. In fact, even if an increase 
of the average number of type-2 leukemic cells is observed during an IT, this eect is 
partially counterbalanced by a reduction in the probability of developing resistance. 
In the case of IT1 therapy, the peak of type-2 leukemic cells shows an increasing trend 
reaching a saturation plateau at about 25% of the total number of leukemic cells. This 
stabilization appears to be sucient to lower the number of patients developing resist-
ance with respect to the other two therapeutic approaches here investigated.
In ﬁgures 8–10 we also highlight the presence of multiple states of dynamical equi-
librium in the number of type-2 leukemic cells in the cases of intermittent drug admin-
istration. In particular, this eect is more evident in the IT21-7 (red symbols/curves) 
case, where lower populated bands (left panels) and peaks (right panels) can be easily 
detected with some periodicity. This ﬁnding is also present in the IT1 case, but with 
lower population densities.
Finally, in ﬁgure 11 we show how intrinsic ﬂuctuations aect the percentage of 
patients developing resistance as a function of time, following the aforementioned ther-
apeutic strategies. The statistical error associated with these values, calculated by 
repeating our set of simulations 10 times, is less than 0.5%. System ﬂuctuations do 
not signiﬁcantly aect the average number of patients developing resistance within the 
ﬁrst 200 d of continuous drug administration, corresponding to essentially the same 
(continuous) therapeutic approach. After dierentiation of the therapy, we ﬁnd an 
advantage of IT over continuous drug administration. Over the whole duration of 2 
years, IT characterized by therapy breaks of 7 d (IT21-7) or 1 d (IT1) shows a reduction 
Figure 11. Percentage of patients developing resistance as a function of time. The 
solid line represents the case of CT. Red dashed and green dotted lines represent 
an IT with breaks of 7 and 1 d, respectively.
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in the average number of patients developing resistance. In particular, a signiﬁcant 
improvement (a reduction of about 5%) is found for IT1 with respect to the traditional 
continuous drug administration.
4. Conclusions
Recent clinical oncology investigations indicate that an IT may be eective in reduc-
ing both the incidence of toxicity and the complications that arise from side eects 
due to long-term continuous treatment with TKIs. In this work, by using a computa-
tional approach, we have studied the eects of ﬂuctuations in a complex cancer system 
of multiple-mutated leukemic cells with the aim of exploring the consequences of an 
intermittent TKI-based therapy on the evolutionary dynamics of normal and cancer-
ous cells in patients aected by CML, with respect to the standard treatment based 
on continuous drug administration. We have studied the evolutionary dynamics of 
healthy and leukemic cells of 5000 simulated patients in the presence of three types of 
therapies: standard daily dose administration (continuous), or delayed by 7 or 1 d time 
lags (intermittent).
We have found that an IT may cause a slight increase of the average number of 
leukemic cells with respect to continuous drug administration, with CML being still 
sensitive to TKIs. Even considering this negative eect, we have found that an IT may 
represent a valid choice in patients with high risk of toxicity. In fact, the presence of a 
slight increase in the average number of leukemic cells is counterbalanced by a reduc-
tion in the average number of resistant clones. These ﬁndings are in agreement with 
recent clinical oncology trials [23, 48]. Our results show that an IT, appropriately tuned 
to speciﬁc patient necessities, should be preferred to the continuous one because of the 
lower risk of toxicity [24], also causing a reduction in the number of patients developing 
resistance to the therapy after two years of treatment. Finally, our IT results clearly 
show the presence of multiple states of dynamical equilibrium in the number of type-2 
leukemic cells. But, unfortunately, the most populated equilibrium state always has the 
highest number of leukemic cells. The possibility of achieving a population reverse in 
CML progression is still an unsolved problem.
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